Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Birault V, Solari R, Hanrahan J, Thomas DY (2013) Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. Curr Opin Chem Biol 17(3):353–360. doi: 10.1016/j.cbpa.2013.04.020
2. Galietta LJ (2013) Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatr Drugs 15(5):393–402. doi: 10.1007/s40272-013-0035-3
3. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordonez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67(1):12–18. doi: 10.1136/thoraxjnl-2011-200393
4. Vertex (2013) Treatment with VX-661 and ivacaftor in a phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation., http://files.shareholder.com/downloads/VRTX/3707093791x0x654519/092B4BA6-2B1C-436C-8790-F69DE75C8040/VRTX_News_2013_4_18_General.pdf
5. Phase 2 proof-of-concept study;Vertex,2014
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献